Cystoid macular edema following travoprost intracameral implant Authors: Heeyah Song, Ariana M. Levin Published: 2026 ABSTRACT PurposeTo describe a case of bilateral cystoid macular edema (CME) that developed following intracameral travoprost implantation, which then resolved after explantation, and to review the association of CME with prostaglandin analogues (PGA).ObservationsThe patient developed CME after intracameral travoprost implantation in each eye. An extensive work up including blood work and aqueous biopsy did not reveal other inflammatory etiologies. Explantation of the travoprost led to resolution of the CME in each eye, suggestive of a temporal association of the implant and the CME.Conclusions & importanceThe association of CME with intracameral PGA might differ from previously reported associations of CME with topical PGA, because intracameral medications provide a sustained dose closer to the retina. Surgeons should consider PGA as a possible etiology in cases of post-procedural CME. Introduction Intracameral drug-eluting implants have been developed as “dropless” intraocular-pressure lowering treatments for glaucoma. These implants provide sustained release of medication without relying on patient adherence and without the topical side effects of eye drops. The iDose TR travoprost intracameral implant (Glaukos Corporation, Aliso Viejo, CA) was FDA-approved in 2023. The titanium implant is surgically placed in the anterior chamber and anchors to the sclera in the angle (Fig. 1). Clinical trials demonstrated high levels of safety. In the Phase III clinical trial, only one subject developed macular edema, and it was attributed to diabetes rather than the implant.1 Therefore, macular edema has not been associated with iDose implantation in clinical trials. Post-market observations and studies contribute to the growing body of knowledge of these implants and similar ophthalmological devices.Fig. 1iDose TR travoprost intracameral implant being implanted under gonioscopic view (left). iDose being explanted with graspers in the anterior chamber (right). iDose TR travoprost intracameral implant being implanted under gonioscopic view (left). iDose being explanted with graspers in the anterior chamber (right). Case A 76-year-old man with mild primary open angle glaucoma (POAG), well-controlled with latanoprost and brimonidine, underwent cataract extraction, intraocular lens implantation, and iDose implantation in the left eye followed by the right eye three weeks later. The surgeries were routine without complication and without difficulty placing the implants. The intraocular lenses were hydrophobic acrylic monofocal implants placed in the bag. Past medical history (PMH) included well-controlled hypertension, hyperlipidemia, and asthma. PMH was negative for diabetes or systemic inflammatory/autoimmune conditions. His right eye measured 23.06mm axial length (AL) and 2.83mm anterior chamber depth (ACD) prior to surgery. His left eye measured 22.76mm AL and 2.77mm ACD. The subject developed cystoid macular edema (CME) and mild diffuse stromal corneal edema in each eye 3-4 weeks after surgery (Fig. 2). The corneal edema was not focal to the implants. Anterior chamber exam demonstrated 0.5+ cell (mixed, white blood cells and pigmented cells). Dilated exam was normal without vitreous cell. The iDose implants were well positioned without evidence of iris chafing (no pigment loss or transillumination defects) and without corneal touch. There was no retained lens fragment. His endothelial cell count was >2000. Bloodwork was normal, including erythrocyte sedimentation rate, C-reactive protein, fluorescent treponemal antibody absorption test, and antinuclear antibody. The subject reported blur without pain or light sensitivity. He denied eye rubbing. His acuity was 20/40, and his intraocular pressure remained below 18mmhg in both eyes.Fig. 2Cystoid macular edema developed after iDose implantation in the right eye (column labeled OD) and in the left eye (column labeled OS). The central macular thickness is labeled in microns. The postoperative weeks (POW) following implantation are labeled. The CME decreased after explantation. Cystoid macular edema developed after iDose implantation in the right eye (column labeled OD) and in the left eye (column labeled OS). The central macular thickness is labeled in microns. The postoperative weeks (POW) following implantation are labeled. The CME decreased after explantation. He was initially treated with topical difluprednate and sodium chloride eye drops. He did not note any improvement in vision. The CME progressed on difluprednate dosed four times daily. The topical latanoprost (tolerated well for years prior to surgery) had been stopped at the time of surgery; the brimonidine (also tolerated well for years prior to surgery) was stopped to eliminate confounding factors. Neither drop was restarted during the recovery period. As the CME worsened, the subject completed a course of oral valacyclovir, which did not improve his exam. The iDose was surgically explanted from the left eye. Following this, the CME improved in the left eye and worsened in the right eye. Then the iDose was surgically explanted from the right eye. Following this, the CME improved in the right eye. Approximately one month after explantation, the CME resolved in both eyes. The corneal edema also resolved. Aqueous biopsy was performed at the time of explantation and was negative for viral polymerase chain reaction. The uncorrected visual acuity 5-6 months after explant was 20/20 in each eye with IOP 12mmhg and 16mmhg. Discussion We present a case in which CME is temporally related to intracameral PGA implantation, and CME resolution is temporally related to explantation. The temporal and dose-response relationships suggest the CME could be a result of the intracameral PGA implant. The lack of response to steroids (as well as the minimal inflammatory cells on exam) suggest against an inflammatory etiology. Other etiologies causing vascular permeability should be considered. The differential diagnosis includes PGA-mediated CME, a reaction to a non-PGA component of the implant, or mechanical micro-trauma from the implant hitting the iris or cornea (e.g. during blinking). The cause-and-effect relationship between PGA medications and CME is controversial. Four systematic reviews found no association of topical PGA with CME in nonsurgical patients and after routine cataract surgery.2, 3, 4, 5 Two systematic reviews suggested there might be a risk after complex surgery.2,4 Notably, these studies only include eyes treated with topical PGA. The subject in our case received intracameral PGA. In the phase III clinical trial of this intracameral travoprost implant, only one subject developed macular edema, and it was not felt to be related to the implant.1 In a phase III clinical trial of a intracameral bimatoprost implant, no macular edema was reported.6 However, retinal optical coherence tomography (OCT) was not included in the scheduled outcome measures of either clinical trial, so subclinical macular edema could have been undetected. Studies demonstrate that topical PGA disrupts the blood-aqueous barrier.7,8 The mechanism of action of PGA medications is related to upregulation of matrix metalloproteinases (MMPs), which remodel extracellular matrix to increase uveoscleral outflow. PGA medications have been shown to act on MMPs in several anatomical structures in the eye, including the ciliary body and trabecular meshwork.9 MMPs also contribute to tissue permeability in the retina.10 The etiology of the corneal edema is also uncertain in this case. Corneal edema in the setting of PGA has been described in case reports.11 MMPs have also been described as potential mediators of corneal edema.12 We recommend that surgeons consider the possibility of CME associated with intracameral PGA implants. It might be prudent to space out PGA-implant surgeries for right and left eyes by enough weeks to assess a patient's risk for CME before proceeding with the second eye. In the rare event that CME does occur, the implant can be easily explanted. CRediT authorship contribution statement Heeyah Song: Writing – review & editing, Writing – original draft. Ariana M. Levin: Writing – review & editing, Writing – original draft, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Patient consent Written consent for publication was obtained from the patient. Authorship All authors attest that they meet the current ICMJE criteria for Authorship. Funding No funding or grant support. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.